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Background
A reimbursement policy for angiotensin-converting
enzyme (ACE) inhibitors based only on controlling
expenditure and not adequate for the patient access to
treatment could not return expected results for long-
term improvement of patients’ health. The study addresses
the need for optimization of the reimbursement policy of
the National Health Insurance Fund in Bulgaria (NHIF)
which is based on payment of a certain percentage of the
reference price within an INN group of drugs, i.e. 25%,
50%, 75% or 100% and covers the Bulgarian reimburse-
ment market of ACE inhibitors, related to pharmaceutical
expenditure and doctors and patients behaviour.
Methods
The study design is related to policy evaluation and impact
assessment of alternative/what-if policy decisions related
to reimbursement policy optimization. The methodology
employed is mathematical modelling and simulation of the
ACE inhibitor drugs market with the aid of computer
modelling and simulation software. Designing and testing
a reimbursement policy based on lower rates of patient
co-payment, while at the same time providing means for
controlling pharmaceutical expenditure, is the focus of
this study. The simulation experiments use INN/ACE
inhibitor prescription data by the NHIF and market data
by IMS Health. These data are analysed and then used in
a system dynamics model accounting for the doctors
prescribing behavior, patient flows and NHIF expenditure,
after which a number of policy experimentations are con-
ducted related to alternative policy scenarios. The what-if
scenarios are performed using an interactive learning
environment or the so-called “management-flight simula-
tor” which enables experimentation through instant
changes in independent variables and their effect on the
dependent variables within the modelled dynamic system
in a historical and forecasted time frame between 2010
and 2020.
Results
The results show that lowering the level of patient co-pay-
ment by raising the level of reimbursement, coupled with
incentives to improve access to therapy and compliance,
would increase NHIF pharmaceutical expenditure on one
hand, but on the other would increase the number of trea-
ted patients and at the same time would provide future
savings from hospitalization of potential non-compliant
and non-treated patients with chronic cardiac disease and
cardiac incidents. Designing optimal reimbursement policy
related to ACE inhibitors is a highly sophisticated process
that needs to account for the dynamic interrelationships
among all key independent and dependent factors within a
systemic perspective, i.e. reimbursement levels, patient co-
payment, access to treatment, compliance to therapy, doc-
tors prescribing behaviour, pharmaceutical expenditure
and government incentives to improve healthcare results.
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